2827-25-0 Usage
Uses
Used in Pharmaceutical Applications:
(6S,8R,9S,10R,13S,14S,17S)-17-hydroxy-6,10,13,17-tetramethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one is used as a therapeutic agent for hormone-related conditions such as delayed puberty and hypogonadism. It is also utilized in the management of breast cancer in women due to its androgenic properties.
Used in Sports and Performance Enhancement:
Although not a recommended or legal application, 17α-methyltestosterone is sometimes used as a performance-enhancing drug by athletes and bodybuilders due to its anabolic effects on muscle growth and strength. However, this use is associated with significant health risks and is strictly regulated as a controlled substance.
Check Digit Verification of cas no
The CAS Registry Mumber 2827-25-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,8,2 and 7 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 2827-25:
(6*2)+(5*8)+(4*2)+(3*7)+(2*2)+(1*5)=90
90 % 10 = 0
So 2827-25-0 is a valid CAS Registry Number.
InChI:InChI=1/C21H32O2/c1-13-11-15-16(19(2)8-5-14(22)12-18(13)19)6-9-20(3)17(15)7-10-21(20,4)23/h12-13,15-17,23H,5-11H2,1-4H3/t13-,15+,16-,17-,19+,20-,21-/m0/s1
2827-25-0Relevant academic research and scientific papers
ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT
-
, (2008/06/13)
The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and devices useful for carrying out both processes.
TRANSDERMAL ADMINISTRATION OF MENT
-
, (2008/06/13)
The present invention relates to transdermal dosage forms for delivery of androgens.
Method for androgen supplementation
-
, (2008/06/13)
A particular group of androgens is not metabolized to their 5α-reduced form in the prostate and other tissues. Thus, administration of these compounds--testosterone derivatives with a non-hydrogen substituent in the 6α or 7α position--allows one to provide androgen supplementation therapy without stimulating abnormal prostate growth. A preferred compound for use in the invention is 7α-methyl-19-nortestosterone.
